Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an announcement.
Grand Pharmaceutical Group Limited reported a significant financial performance for the year ended December 31, 2024, with a 10.6% increase in revenue and a 31.3% rise in profit attributable to its owners. The company has made substantial investments in research and development, particularly in its nuclear medicine segment, which saw a 176.6% revenue increase. This growth reflects the company’s strategic focus on innovation and expansion amid China’s evolving pharmaceutical landscape, characterized by systemic reforms and increased emphasis on innovative drugs.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates within the pharmaceutical industry, focusing on the development and commercialization of innovative medical products. The company is involved in research and development, particularly in the nuclear medicine anti-tumor diagnosis and treatment segment, and aims to enhance its market presence through strategic expansion and innovation.
YTD Price Performance: 10.42%
Average Trading Volume: 3,642,419
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$18.81B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.